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Introduction 
 
Alcoholism is defined as physical dependence on alcohol 
and loss of control over alcohol intake (Retrieved from 
MayoClinic).  This addiction can have severe health, 
economic, and work-related consequences (Retrieved from 
MayoClinic).   Many factors such as mental health and social 
relationships have been found to affect the likelihood of an 
individual becoming alcohol-dependent, and genetics is one 
of them (Retrieved from MayoClinic).  Three decades ago 
scientists noticed a strange phenomenon in certain Asian 
populations: after consuming a small amount of alcohol, they 
begin to experience facial flushing, chest palpitations, and 
dizziness (Mizoi et al., 1979).  Research later revealed a 
mutation in a specific gene-aldehyde dehydrogenase 2 
(ALDH2) that leads to the inactive form of the enzyme which 
causes these symptoms which are collectively known as the 
alcohol flush reaction (Yoshida et al., 1984).  Normal ALDH2 
can break down acetaldehyde, the byproduct of ethanol 
metabolism; however, inactive ALDH2 cannot (Zakhari, 
2006).  Scientists have now made use of the inactive ALDH2 
phenotype to treat alcoholism; that is, they can elicit the 
alcohol flush reaction in patients so as to discourage them 
from further drinking. 
 Ocaranza et al. (2008) found that a single 
administration of an anti-Aldh2 antisense gene can 
significantly inhibit ethanol intake in alcohol-dependent rats.  
This gene therapy works by inactivating ALDH2 which 
consequently elevates acetaldehyde levels (Ocaranza et al., 
2008).  Though this treatment has been shown to be more 
effective than disulfiram (Antabuse®), a drug currently on the 
market, Ocaranza et al. (2008) have yet to look at the 
consequences of acetaldehyde buildup in the treated rats.  It 
is important to carry out a follow up because acetaldehyde is 
a known carcinogen that can lead to the formation of cancer-
causing DNA adducts such as 1,N
2
-propanodeoxyguanosine 
(Zakhari, 2006).  People with the defective ALDH2 
phenotype have exhibited higher risks for gastrointestinal 
cancer than people with the normal phenotype (Yokoyama et 
al., 1998), thus it is critical to assess the effects of inducing 
acetaldehyde accumulation by inactivating ALDH2 in rats 
treated with anti-Aldh2 antisense gene. 
 
Specific Aims 
 
 The first goal is to determine whether administering anti-
Aldh2 antisense gene induces a high rate of cell 
differentiation (hyperproliferation) and an increase in the 
number of cells (hyperplasia) in the gastrointestinal tract of 
alcohol-dependent rats.  Abnormal cell differentiation and 
proliferation are characteristic signs of cancer (Homann et 
al., 1997). Thus, if the experiment is able to detect both 
characteristics in the treated rats but not the untreated rats, it 
can be concluded that cancer has developed after 
administering the gene therapy.  The second goal is to 
determine whether the reason behind altered differentiation 
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and proliferation is elevated acetaldehyde level in the 
gastrointestinal tract.  The hypothesis is that the tissues 
exhibiting hyperproliferation and hyperplasia in the rats that 
received the antisense gene treatment have increased 
acetaldehyde buildup compared to the animals that did not 
receive the antisense gene treatment. 
 
Experimental Proposal 
 
Two experiments will be conducted to assess the 
consequences of genetically inactivating ALDH2 in alcohol-
dependent rats that are consuming small amounts of ethanol 
regularly.  Both will be extensions of the study done by 
Ocaranza et al. (2008) where they first discovered and 
tested the efficacy of the anti-Aldh2 antisense gene 
treatment.  Following the methods used in the Ocaranza et 
al. (2008) study, anti-Aldh2 adenoviral vector (AdV-AS) that 
generates the antisense RNA will be prepared.  Twenty 
alcohol-preferring rats bred selectively for their high alcohol 
intake will either be administered the AdV-AS or the control 
vector (AdV-control) not carrying the transgene (Ocaranza et 
al., 2008).  From the morning of day 1 onwards, the animals 
will be allowed access to only 0.6 g/kg of 10% ethanol 
solution every day for 8 months (Homann et al., 1997; 
Ocaranza et al., 2008).  The amount of alcohol fed to the 
rats is determined from the Ocaranza et al. (2008) study 
where they found that when the rats treated with the AdV-AS 
were allowed free access to ethanol, they consumed only 
the aforementioned amount each day.  If alcohol intake is 
not controlled, the rats not treated with the antisense gene 
will consume significantly more alcohol than the treated rats 
because the animals are originally alcohol-dependent 
(Ocaranza et al., 2008). 
 After the 8 month period, the rats will be killed 
under ether anesthesia, and tissue specimens will be 
dissected from the oral cavity, the esophagus, and the 
stomach.  These specific locations from the gastrointestinal 
tract are chosen because cancers of these areas have been 
associated with the inactive ALDH2 phenotype (Yokoyama 
et al., 1998).  To look for signs of cancer, the tissue samples 
will be immunohistochemically stained for markers of cellular 
differentiation or proliferation (Homann et al., 1997).  Light 
microscopy with an eyepiece containing grid lines will then 
be used to measure the average epithelial thickness of each 
sample (Homann et al., 1997).  The staining patterns and the 
epithelial thickness measurements of the rats treated with 
the antisense gene and the rats treated with the control 
vector will be compared using the unpaired Student’s t test 
(Homann et al., 1997).   
 If hyperproliferation and hyperplasia can be found 
in the tissue specimens, a second experiment will be 
conducted to determine if they are caused by increased 
levels of acetaldehyde.  Tissue samples will be dissected 
from the same two groups of rats and again from the oral 
cavity, the esophagus, and the stomach.  Using the methods 
described in Ohata et al. (1996), the tissues will be 
homogenized, and the acetaldehyde present will be 
derivatized to 2,4-dinitrophenylhydrazone.  This substance 
will then be analyzed with a GC14A gas chromatograph, 
equipped with a 
63
Ni electron-capture detector.  This assay 
can determine minute amounts of acetaldehyde in biological 
samples (Ohata et al., 1996).  Differences between the 
experimental and control groups will be analyzed by one-
way analysis of variance, followed by the Turkey-Kramer 
multiple comparison test (Visapaa et al., 2002).   
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 For the proposed experiments, there could be two 
possible outcomes.  One is that hyperproliferation and 
hyperplasia are seen in the tissue samples of the rats 
treated with the anti-Aldh2 antisense gene compared to the 
untreated rats; acetaldehyde level is higher in these tissues 
as well, which provides evidence that acetaldehyde plays a 
role in the development of cancerous cells.  These results 
would show that the gene therapy for alcoholism developed 
by Ocaranza et al. (2008) can induce cancer development in 
the animal model.  Thus the proposed treatment would not 
be safe for human use. 
The other possibility is that neither 
hyperproliferation nor hyperplasia in the rats treated with the 
anti-Aldh2 antisense gene can be detected, and there is no 
significant increase in acetaldehyde level.  This would 
indicate that the newly discovered gene therapy does not 
increase the risks of gastrointestinal cancer in the animal 
model.  Additionally, there are possible negative 
consequences associated with applying this treatment to 
human use that must be considered.  An adenoviral vector is 
used to transport the anti-Aldh2 antisense gene into the 
alcohol-dependent rats.  The major disadvantage of using 
such vectors is the possibility of the host mounting an 
immune response upon vector delivery as adenoviral vectors 
are based on an extremely common human pathogen 
(Reece, 2004).  Also, Ocaranza et al. (2008) did not check 
for side effects in the alcohol-dependent rats after treatment 
with the antisense gene.  Similar to the anti-Aldh2 antisense 
gene treatment, disulfiram discourages alcoholic patients 
from further drinking by eliciting the inactive ALDH2 
phenotype (Garver et al., 2001).  However, this drug has 
many severe side effects such as sensory and motor 
neuropathies (Garver et al., 2001).  Therefore, it would be 
important to determine whether there are serious side effects 
associated with this new form of treatment.  Further research 
on both the safety issues of using adenoviral vectors and the 
possibility of side effects should be included in the next steps 
taken to determine whether the anti-Aldh2 antisense gene 
treatment is safe for clinical use. 
 
Conclusion 
 
The proposed research will determine whether the anti-
Aldh2 antisense gene, which has previously shown to 
effectively protect against alcoholism, can cause 
hyperproliferation and hyperplasia (both indicative of cancer) 
in the gastrointestinal tract when administered to an animal 
model.  The results from these experiments can potentially 
protect patients from therapies that could lead to cancer, and 
can also be helpful in the development of better treatments 
for alcoholism. 
 
Note: Eukaryon is published by students at Lake Forest 
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